High Court Won't Review Feraheme Investor Class Action

Law360, New York (October 7, 2013, 3:26 PM EDT) -- The U.S. Supreme Court on Monday refused to hear an appeal of the First Circuit’s revival of a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks associated with its iron deficiency treatment Feraheme.

In a brief order, the high court denied AMAG’s petitions for writ of certiorari without comment, but noted that Justice Samuel Alito took no part in the decision.

The investors, led by Silverstrand Investments LLC, Safron Capital Corp. and Briarwood Investments Inc., filed the...
To view the full article, register now.